Efflux of the Tyrosine Kinase Inhibitors Imatinib and Nilotinib (AMN107) Is Mediated by ABCB1 (MDR1)-Type P-Glycoprotein.
Marius Dohse(Center for Cancer Research), Christian Scharenberg(National Institutes of Health), Susan E. Bates(The Nature Conservancy), Cornelia Brendel(Philipps University of Marburg), Andreas Neubauer(RWTH Aachen University), Robert W. Robey(National Institutes of Health)
Cited by 10
Related Papers
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance
|Cellular and Molecular Life Sciences|2001|685
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573